Orion S.A.
OECOrion S.A. (OEC) is a pharmaceutical company based in Greece, specializing in the development, manufacturing, and marketing of a range of pharmaceutical products. The company focuses on areas such as prescription medicines, over-the-counter (OTC) products, and generics, serving both domestic and international markets. Known for its commitment to innovation and quality, Orion has established a strong presence in the pharmaceutical industry in Southeastern Europe and beyond.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 20, 2026 | $0.02 | 2025-12-12 | 2025-12-12 |
| October 8, 2025 | $0.02 | 2025-07-07 | 2025-07-07 |
| July 2, 2025 | $0.02 | 2025-06-11 | 2025-06-11 |
| April 4, 2025 | $0.02 | 2025-03-13 | 2025-03-13 |
| January 21, 2025 | $0.02 | 2024-12-13 | 2024-12-13 |
Dividends Summary
- Consistent Payer: Orion S.A. has rewarded shareholders with 33 dividend payments over the past 12 years.
- Total Returned Value: Investors who held OEC shares during this period received a total of $4.10 per share in dividend income.
- Latest Payout: The most recent dividend of $0.02/share was paid 3 days ago, on January 20, 2026.
- Yield & Schedule: OEC currently pays dividends quarterly with an annual yield of 1.29%.
- Dividend Growth: Since 2014, the dividend payout has decreased by 97.5%, from $0.83 to $0.02.
- Dividend Reliability: OEC has maintained or increased its dividend for 17 consecutive payments.
Company News
Orion reported Q3 2025 net sales of €423.2 million and operating profit of €121.0 million, with growth in most business divisions. The company discontinued ODM-105 insomnia treatment and plans to focus on oncology research and biological candidates.
Orion reported Q3 2025 financial results with a revenue of €423.2 million and operating profit of €121.0 million. The company saw strong growth in basic business, particularly in Nubeqan sales and royalties, while experiencing a decline compared to the previous year due to significant milestone payments in 2024.
Orion reported strong Q2 2025 financial results with 26.9% revenue growth to €416.5 million and 58.9% increase in operating profit to €104.6 million. The company upgraded its full-year outlook, expecting revenue of €1,630-1,730 million and operating profit of €400-500 million.
Orion Oyj has upgraded its financial guidance for 2025, expecting higher revenue and operating profit due to faster-than-anticipated product sales and royalty income in the first half of the year.
Orion and Glykos Finland Oy have expanded their research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs) for cancer treatment. The expanded agreement gives Orion the right to use Glykos' ADC technologies in three new ADC projects, in addition to the three projects already agreed upon.
